Get the Stockscreener App
5.205
2.66%
0.135
Humacyte Inc stock is traded at $5.205, with a volume of 1.29M.
It is up +2.66% in the last 24 hours and down -4.32% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$5.07
Open:
$5.19
24h Volume:
1.29M
Relative Volume:
0.45
Market Cap:
$635.40M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-5.9828
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
-2.16%
1M Performance:
-4.32%
6M Performance:
+18.03%
1Y Performance:
+134.46%
1-Day Range:
$5.11
$5.41
1-Week Range:
$4.85
$5.58
52-Week Range:
$2.0838
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Investors to Inquire about Securities Investigation - AccessWire
Humacyte (NASDAQ:HUMA) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte (NASDAQ:HUMA) Trading Down 5%Here's Why - MarketBeat
Humacyte wins special advanced-therapy designation for ATEV - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out - AccessWire
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out | NDAQ:HUMA | Press Release - Stockhouse Publishing
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors - MSN
Humacyte (NASDAQ:HUMA) Trading 7.5% HigherHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Humacyte, Inc. (HUMA) And Encourages Stockholders to Connect - AccessWire
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire
Humacyte StockInvestors of Humacyte Encouraged to Contact Kehoe Law Firm, P.C.HUMA - AccessWire
Revisiting Humacyte (NASDAQ:HUMA) - Seeking Alpha
Humacyte, Inc. (NASDAQ:HUMA) Receives $10.00 Consensus Target Price from Analysts - MarketBeat
Humacyte's SWOT analysis: HAV tech stock poised for growth amid challenges - Investing.com Canada
(HUMA) Trading Signals - Stock Traders Daily
Humacyte (NASDAQ:HUMA) Stock Price Down 2.9%Here's Why - MarketBeat
Humacyte reports positive trial results for hemodialysis access By Investing.com - Investing.com Canada
Humacyte reports positive trial results for hemodialysis access - Investing.com India
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire Inc.
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA) - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024 - The Manila Times
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Humacyte Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors - MSN
TD Cowen reaffirms Buy rating on Humacyte stock, believes FDA observations are resolved - Investing.com
Humacyte (NASDAQ:HUMA) Shares Gap UpTime to Buy? - MarketBeat
BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Piper Sandler maintains neutral on Humacyte - Investing.com
Humacyte, Inc. (NASDAQ:HUMA) Sees Large Increase in Short Interest - MarketBeat
Humacyte (NASDAQ:HUMA) Trading 6.5% HigherHere's What Happened - MarketBeat
When (HUMA) Moves Investors should Listen - Stock Traders Daily
‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab - The Wall Street Journal
AQR Capital Management LLC Grows Stock Position in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Given Buy Rating at Benchmark - MarketBeat
Millennium Management LLC Purchases 1,334,641 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
Humacyte Launches $30M Stock and Warrants Offering - Yahoo Finance
Humacyte to sell 5.68M shares at $5.28 in registered direct offering - TipRanks
Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) PT at $9.80 - MarketBeat
Marshall Wace LLP Purchases 450,031 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte secures $30 million through stock and warrants sale By Investing.com - Investing.com South Africa
Humacyte prices $30M securities offering - MSN
Humacyte secures $30 million through stock and warrants sale - Investing.com India
Humacycle Ekes up on Share Offering - Baystreet.ca
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):